LLY•benzinga•
Eli Lilly To Acquire Scorpion Therapeutics' Nutant-selective PI3Kα Inhibitor Program; Scorpion Shareholders Could Receive Up To $2.5M In Cash
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga